Memphasys

Memphasys Goodwill

Goodwill for Memphasys (MEM.AX) pr. 22. okt. 2026 er 338.896,00 AUD. I foregående år var Goodwill 338.896,00 AUD — en ændring på 0,00 % (lavere).

Goodwill

338.896,00AUD

YoY

0,00%

Senest opdateret:

Goodwill for Memphasys er 2017 338.896,00 AUD. Goodwill for Memphasys var 2016 338.896,00 AUD. Det falder dermed med 0,00% lavere sammenlignet med året før.

Memphasys Goodwill historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

Goodwill
Dato
Goodwill
1. jan. 2014
1,54 Mio. AUD
1. jan. 2015
338.896,00 AUD
1. jan. 2016
338.896,00 AUD
1. jan. 2017
338.896,00 AUD
Memphasys Goodwill historik
ÅRGoodwillYoY
338.896,00AUD0,00%
338.896,00AUD0,00%
338.896,00AUD-78,06%
1,54 Mio.AUD—

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Memphasys Aktieanalyse

Hvad laver Memphasys? Memphasys Ltd. develops medical devices, diagnostics, and media for assisted reproduction technology (ART) in humans and animals. The company's product pipeline includes Felix, a patented automated device for separating high-quality sperm from semen in human IVF procedures, ROSA, an in vitro diagnostic for assessing oxidative stress in semen and blood samples, and AI-Port, a system for storing and transporting animal semen without freezing for up to four days. Felix targets the global IVF market, ROSA serves clinics and research facilities analyzing reproductive health, and AI-Port is designed for livestock artificial insemination providers. The company monetizes through direct sales of these proprietary products to healthcare providers, fertility clinics, and agricultural biotechnology firms. Felix, with its patented technology for DNA-safe sperm separation, addresses a significant market need in human fertility treatments. ROSA provides diagnostic capabilities for clinics evaluating oxidative stress in reproductive samples, while AI-Port offers a competitive advantage in livestock breeding by eliminating the need for frozen semen transport. These products are sold directly to specialized buyers within their respective sectors without intermediaries. The company generates revenue primarily from the sale of its three core products: Felix for human IVF, ROSA for diagnostic assessments, and AI-Port for animal semen storage and transport. These products target distinct segments—human fertility clinics, reproductive health research institutions, and livestock artificial insemination businesses—each with clear purchasing patterns and demand drivers. Memphasys focuses on selling directly to these end-users rather than through third-party distributors. Memphasys er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Memphasys aktie

Goodwill for Memphasys er 338.896,00 AUD i 2017.

Goodwill for Memphasys ændrede sig fra 338.896,00 AUD til 338.896,00 AUD, hvilket repræsenterer en ændring på 0,00 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Goodwill Memphasys siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Goodwill er præmien betalt over fair markedsværdi ved en opkøb. Det repræsenterer immateriel værdi såsom mærkegenkendelse, kundeforhold og intellektuel ejendom.

Goodwills AUD er en vigtig faktor for investorer. Ændringer i denne nøgletal kan signalere forbedrede eller forværrede fundamentale forhold, hvilket kan påvirke aktiekursen. På Eulerpool kan du følge Goodwills Memphasys historisk.

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Balance — Memphasys

Alle nøgletal — Memphasys